Pain affects approximately 30% of people and places a large economic and social burden on
society. Despite the availability of a range of analgesics, complete alleviation of symptoms still rarely
occurred. Effective and safe drugs for the treatment of pain are still an unmet clinical need. In recent
years, the voltage-gated sodium channels (VGSCs) have been recognized as potential targets for analgesic
development. VGSCs are major players in generating and propagating action potentials. They
represent an appealing target for the development of new and safer drugs in the treatment of pain. The
majority of the research has been focused on Nav1.7 in particular, other VGSC subtypes, such as
Nav1.1, Nav1.3, Nav1.6, Nav1.8 and Nav1.9 have recently come to the forefront of analgesic research.
Peptides from scorpion have been proved to be a valuable tool in neuroscience, playing a significant
role in the identification and characterization of VGSC subtypes and many of them resulting in analgesia
in pain. This review assesses the potential of scorpion toxin targeting VGSCs for analgesic development.
Keywords: Pain, VGSC, peptide, scorpion toxin, autoimmune diseases, NSAIDs.
Rights & PermissionsPrintExport